Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can exercise tame hunger hormones? new study investigates

NCT ID NCT04581980

Knowledge-focused Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how different exercise intensities affect ghrelin, a hormone that controls hunger, in 40 adults with obesity or prediabetes. Participants cycled on a stationary bike while researchers measured ghrelin levels, appetite, and blood vessel function. The goal was to understand how exercise might influence metabolism and appetite regulation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
exercise (cycling)
What this could lead to
If successful, this could help explain how exercise affects appetite and metabolism, potentially guiding future weight management strategies.
What could go wrong
This is a small, completed observational study with only 40 participants, so results may not apply broadly. It does not test a treatment or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Oct 2020

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18-55 years of age * BMI between 18-40 kg/m2 * Untrained (reports less than 2 days/week of exercise) * Weight stable (no significant loss/gain of more than 3kg in the past 3 months) * Females must be premenopausal and report normal menstrual cycles Exclusion Criteria: * History of diabetes, gastrointestinal disease, or endocrine disorder * Smoking (must have quit at least 6 months prior) * Disordered eating * Females currently pregnant or undergoing fertility treatments * The following medications (due to their effect on insulin sensitivity ,endothelial function and/or ghrelin secretion): Synthetic growth hormone, metformin, synthetic insulin, sulfonylureas, meglitinides, Thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors , biguanides, alpha-glucosidase inhibitors, phosphodiesterase inhibitors, beta-blockers, alpha-blockers, ACE-inhibitors, ARB's, fibrates, glucocorticoids, olanzapine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular risk factor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance Motor Activity Obesity obesity disorder prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular risk factor Insulin resistance Obesity

Contacts and locations

Locations

  • University of Virginia

    Charlottesville, Virginia, 22902, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.